Previous 10 | Next 10 |
Omnicell (NASDAQ: OMCL ): Q2 Non-GAAP EPS of $0.67 beats by $0.04 ; GAAP EPS of $0.37 beats by $0.04 . Revenue of $217.4M (+15.2% Y/Y) beats by $3.27M . Press Release More news on: Omnicell, Inc., Earnings news and commentary, Tech stocks news,
Record GAAP and non-GAAP revenues of $217.4 million, up 15.2% year-over-year GAAP net income per diluted share of $0.37, up 131.3% year-over-year Non-GAAP net income per diluted share of $0.67, up 45.7% year-over-year Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medic...
SAN FRANCISCO, July 24, 2019 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in Omnicell, Inc. (NASDAQ: OMCL) to the securities class action, Bursick v. Omnicell, Inc. et al., No. 3:19-cv-04150, filed in the U.S. District Court for the Northern District of Californi...
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Omnicell, Inc. (NASDAQ: OMCL) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between October 25, 2018 and June 11, 2019. Omnicell provides automation and business analy...
NEW YORK, July 19, 2019 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Omnicell, Inc. (“Omnicell” or the “Company”) (Nasdaq: OMCL) in the United States District Court for the Northern District of Cal...
NEW YORK, July 19, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Omnicell, Inc. (“Omnicell” or the “Company”) (NASDAQ: OMCL) of the September 16, 2019 deadline to seek the role of lead plaintiff in...
Combination of Automation and Data Analytics Will Enhance Control and Efficiency to Free Up Pharmacists to Support Patient Care Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announ...
SAN FRANCISCO, CA / ACCESSWIRE / July 17, 2019 / Hagens Berman Sobol Shapiro LLP reminds investors Omnicell, Inc. (NASDAQ: OMCL) of the firm’s ongoing investigation of possible securities law violations related to potential improper accounting. If you purchased or otherwis...
Glancy Prongay & Murray LLP (“GPM”) announces the continuation of its investigation on behalf of Omnicell, Inc. (“Omnicell” or the “Company”) (NASDAQ: OMCL ) investors concerning the Company and its officers’ possible violations of feder...
SAN FRANCISCO , July 15, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, with nine offices in eight cities around the country and eighty attorneys, updates investors Omnicell, Inc. (NASDAQ: OMCL) on the firm's ongoing investigation of possible securities law violations related ...
News, Short Squeeze, Breakout and More Instantly...
FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"),...
Multi-year Innovation Program Designed to Maximize Value and Outcomes for XT Automated Dispensing System Omnicell, Inc. (Nasdaq:OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced XT Amplify, a multi...
Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, will release its financial results for the first quarter 2024, before market open on Thursday, May 2, 2024. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET...